Skin Graft Except for Skin Ulcer or Cellulitis with MCC DRG Reimbursement

DRG 576 encompasses inpatient admissions for skin graft procedures (excluding those for skin ulcers or cellulitis) accompanied by a Major Complication or Comorbidity; it denotes higher clinical complexity. This designation matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity raises the relative weight and associated Medicare payment to reflect greater resource utilization.

DRG 576 Overview

DRG 576 covers hospital admissions for skin graft procedures not performed for treatment of skin ulcers or cellulitis and that include a Major Complication or Comorbidity. Typical cases include extensive burn coverage, traumatic skin loss, or large reconstructive grafting where significant acute physiologic disturbances or severe comorbid conditions are present. This Diagnosis-Related Group has higher relative payment weight because the presence of a Major Complication or Comorbidity increases expected resource use, length of stay, and intensity of inpatient services under Centers for Medicare & Medicaid Services payment policy.

Acute surgical technique and perioperative optimization trials: randomized or prospective cohort studies comparing different skin graft harvesting and fixation methods, adjunctive intraoperative technologies (such as negative-pressure wound therapy applied immediately over grafts), and enhanced perioperative protocols (analgesia, hemostasis, and infection prophylaxis). These studies enroll adult inpatients undergoing split-thickness or full-thickness skin grafts for traumatic wounds, burns, or reconstructive defects excluding primary ulcers or cellulitis, with a focus on graft take rates, early complications (hematoma, seroma, infection), and length of stay. Results are directly relevant to surgeons and hospital revenue managers because improvements in graft survival and reduced complications can shorten LOS and ICU needs, lower readmission risk, and influence resource utilization and DRG case-mix costs.
Comparative effectiveness and cost-effectiveness studies of biologic and dressing adjuncts to grafting: observational cohorts and pragmatic randomized trials evaluating topical biologic matrices, cellular skin substitutes, advanced dressings, or antibiotics-impregnated materials used as adjuncts to standard grafting in complex wounds without primary ulceration or cellulitis. These trials typically enroll medically complex inpatients (eg, patients with peripheral vascular disease, diabetes mellitus, immunosuppression, or large surface-area defects) to compare outcomes such as time to definitive wound closure, need for re-grafting, secondary infection rates, and total inpatient episode costs. Payers and hospital administrators rely on this evidence to decide reimbursement policies and formulary placement for expensive adjuncts and to predict downstream costs associated with failed grafts or prolonged hospitalization under DRG 576.
Post-discharge outcomes and rehabilitation research: prospective registry studies and longitudinal outcomes research tracking functional recovery, wound-related readmissions, outpatient dressing change needs, and quality-of-life after inpatient skin grafting for non-ulcer/cellulitis indications. These studies follow diverse discharge populations—including elderly patients, those with limited social support, and patients requiring home health or skilled nursing facility care—to identify predictors of readmission, durable wound closure, and long-term resource use. Findings inform discharge planning protocols, transitional care interventions, and payer strategies to reduce preventable readmissions and optimize post-acute spending tied to episodes bundled under this DRG.

Acute surgical technique and perioperative optimization trials: randomized or prospective cohort studies comparing different skin graft harvesting and fixation methods, adjunctive intraoperative technologies (such as negative-pressure wound therapy applied immediately over grafts), and enhanced perioperative protocols (analgesia, hemostasis, and infection prophylaxis). These studies enroll adult inpatients undergoing split-thickness or full-thickness skin grafts for traumatic wounds, burns, or reconstructive defects excluding primary ulcers or cellulitis, with a focus on graft take rates, early complications (hematoma, seroma, infection), and length of stay. Results are directly relevant to surgeons and hospital revenue managers because improvements in graft survival and reduced complications can shorten LOS and ICU needs, lower readmission risk, and influence resource utilization and DRG case-mix costs.
Comparative effectiveness and cost-effectiveness studies of biologic and dressing adjuncts to grafting: observational cohorts and pragmatic randomized trials evaluating topical biologic matrices, cellular skin substitutes, advanced dressings, or antibiotics-impregnated materials used as adjuncts to standard grafting in complex wounds without primary ulceration or cellulitis. These trials typically enroll medically complex inpatients (eg, patients with peripheral vascular disease, diabetes mellitus, immunosuppression, or large surface-area defects) to compare outcomes such as time to definitive wound closure, need for re-grafting, secondary infection rates, and total inpatient episode costs. Payers and hospital administrators rely on this evidence to decide reimbursement policies and formulary placement for expensive adjuncts and to predict downstream costs associated with failed grafts or prolonged hospitalization under DRG 576.
Post-discharge outcomes and rehabilitation research: prospective registry studies and longitudinal outcomes research tracking functional recovery, wound-related readmissions, outpatient dressing change needs, and quality-of-life after inpatient skin grafting for non-ulcer/cellulitis indications. These studies follow diverse discharge populations—including elderly patients, those with limited social support, and patients requiring home health or skilled nursing facility care—to identify predictors of readmission, durable wound closure, and long-term resource use. Findings inform discharge planning protocols, transitional care interventions, and payer strategies to reduce preventable readmissions and optimize post-acute spending tied to episodes bundled under this DRG.

OpenPayer

Summary & Overview

Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

DRG 576 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes